Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-340-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
No bioaccumulation potential is expected.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
There is no specific requirement to generate Toxicokinetic information according to REACH Regulation (EC) No 1907/2006. Annex I, Section 1.0.2 states that “the human health hazard assessment shall consider the toxicokinetic profile (i.e. absorption, metabolism, distribution and elimination) of the substance”. Furthermore, REACH announces in Annex VIII (Section 8.8.1) that one should perform “assessment of the toxicokinetic behaviour of the substance to the extent that can be derived from the relevant available information”. The toxicokinetic behaviour derived from available data on the dissociation substances but also taking in great consideration the physicochemical properites of the substance. Further testing is not considered as necessary since the toxicological profile of the substance (and dissociation substances) can be predicted/ evaluated. The assessment of TK profile (absorption, metabolism, distribution, excretion) is therefore assessed to the extent that can be derived from the relevant available information.
Absorption by the dermal and inhalation route is not expected; the route of maximum absorption considered as potentially relevant for substance is the oral one. Once in the blood the substance is expected to dissociate into triethanolamine, sodium and perchlorate following therefore their distribution, metabolism and excretion profile.
Perchlorate is readily and extensively absorbed from the gastrointestinal tract in both humans and rats. Peak blood concentrations in rat by 3 h, in humans perchlorate in urine is noted from 10 minutes after ingestion. Following absorption, it is widely distributed in the body (human serum, plasma, urine, saliva and breast milk) with the highest concentrations occuring in the thyroid. Evidence indicates that it undergoes very little, if any metabolism. Then it is rapidly excreted mainly in the urine as unchanged parent compound (half-life in rats is 8 -20 hrs, in humans is 8 -12 hrs). Almost all radiolabelled perchlorate (99.5 %) is recovered from urine within 48 hrs following inravenous administrtion in rats.
In a comparative pharmacokinetics and metabolism study on triethanolamine, dermal absorption of [14C]-triethanolamine was slower and less extensive in F344 rats than in C3H/HeJ mice, although the tissue distribution of radioactivity was similar. In mice that received a single 1000 mg/kg dermal application, approximately 60 % of the radioactivity was recovered from the urine and 20 % was recovered from the feces 48 hours after dosing; less than 10 % was detected in the skin at the site of application. More than 95 % of the radioactivity recovered in the urine was identified as the parent compound, indicating that triethanolamine does not undergo extensive biotransformation in mice. The serum half-life of [14C]-triethanolamine in mice was approximately 9.5 hrs after either a 1 mg/kg intravenous injection or a 1000 mg/kg dermal application. In rats, a single oral dose (2 to 3 mg/kg) of [14C]-triethanolamine was rapidly absorbed and excreted mainly in the urine as unchanged parent compound. Twenty-four hours after dosing, 53 % of the radioactivity was recovered in the urine and 20 % was recovered in the feces. Also, after multiple oral administration to male and female rats, triethanolamine was mainly excreted unchanged. The urinary and faecal excretion ratio of unchanged triethanolamine remained constant throughout the treatment period (for five to six days) in both males and females. A small amount of triethanolamine (1.4–2.7 %) was excreted as glucuronide conjugates.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.